Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
976 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02993731 | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma(CanStem111P) | completed | Phase 3 | 1,134 | Sumitomo Pharma America, Inc.INDUSTRY | 20 | Nov 15, 2023 | clinicaltrials |
| NCT03297346 | Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer(EARLY-HEART) | completed | N/A | 250 | French Nuclear Safety and Radiation Protection Authority (ASNR)OTHER_GOV |
| 5 |
| Nov 7, 2023 |
| clinicaltrials |
| NCT05032339 | Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer | completed | — | 208 | Becton, Dickinson and CompanyINDUSTRY | 5 | Oct 30, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT04135963 | A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal) | completed | — | 62 | TakedaINDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02312258 | A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | completed | Phase 3 | 706 | TakedaINDUSTRY | 35 | Sep 21, 2023 | clinicaltrials |
| NCT04727593 | The Modulatory Role of Internet MBCT on Extracellular Vesicles and Distress in Cancer Patients - Study Protocol(MINDGAP) | unknown | N/A | 111 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 511 | Novartis PharmaceuticalsINDUSTRY | 20 | Aug 21, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT00542308 | Zalutumumab in Non-curable Patients With SCCHN | completed | Phase 2 | 90 | GenmabINDUSTRY | 11 | Aug 3, 2023 | clinicaltrials |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)(REVEAL 1) | completed | Phase 3 | 201 | Inovio PharmaceuticalsINDUSTRY | 19 | Jul 27, 2023 | clinicaltrials |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)(apact) | completed | Phase 3 | 866 | CelgeneINDUSTRY | 21 | Jun 28, 2023 | clinicaltrials |
| NCT05469425 | Home-based Preoperative Exercise Training for Lung Cancer Patients Undergoing Surgery | completed | N/A | 46 | Instituto Politécnico de LeiriaOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01321554 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)(SELECT) | completed | Phase 3 | 392 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT02285062 | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma(ROBUST) | completed | Phase 3 | 570 | CelgeneINDUSTRY | 21 | Jun 22, 2023 | clinicaltrials |
| NCT01734928 | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma(OPTIMISMM) | completed | Phase 3 | 559 | CelgeneINDUSTRY | 22 | Jun 6, 2023 | clinicaltrials |
| NCT04547946 | Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) | completed | — | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT04319354 | Evaluation of cfDNA as a Marker of Response in Rectal Cancer | completed | N/A | 50 | Hospital Pedro HispanoOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05860621 | Promoting Physical Activity in Breast Cancer Survivors on Aromatase Inhibitors(PAC-WOMAN) | unknown | N/A | 122 | Grupo LusófonaOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT01698918 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer(BOLERO-4) | completed | Phase 2 | 202 | Novartis PharmaceuticalsINDUSTRY | 13 | May 3, 2023 | clinicaltrials |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar TherapeuticsINDUSTRY | 17 | Apr 21, 2023 | clinicaltrials |
| NCT02915744 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine(ATTAIN) | completed | Phase 3 | 178 | Nektar TherapeuticsINDUSTRY | 10 | Apr 14, 2023 | clinicaltrials |
| NCT02756611 | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)(VENICE I) | completed | Phase 3 | 258 | AbbVieINDUSTRY | 21 | Apr 10, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | unknown | Phase 3 | 820 | National Cancer Institute, NaplesOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT02726581 | An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma(CheckMate 602) | completed | Phase 3 | 170 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 27, 2023 | clinicaltrials |
| NCT02869399 | Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention(DietINT) | completed | N/A | 94 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 6 | Mar 13, 2023 | clinicaltrials |
| NCT02197351 | Narrow Band Imaging for Gastric Neoplasia | unknown | N/A | 220 | University of Southern CaliforniaOTHER | 2 | Mar 6, 2023 | clinicaltrials |
| NCT01938001 | Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)(AUGMENT) | completed | Phase 3 | 358 | CelgeneINDUSTRY | 17 | Feb 22, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT04366713 | A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | completed | Phase 2 | 6 | Puma Biotechnology, Inc.INDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT01721876 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | completed | Phase 3 | 666 | Boehringer IngelheimINDUSTRY | 25 | Feb 8, 2023 | clinicaltrials |
| NCT03909386 | Non-interventional Study on Patients With Atrial Fibrillation and Cancer(BLITZ-AFCancer) | completed | — | 1,514 | Heart Care FoundationOTHER | 6 | Jan 12, 2023 | clinicaltrials |
| NCT01796002 | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | completed | Phase 3 | 421 | The Lymphoma Academic Research OrganisationOTHER | 8 | Jan 10, 2023 | clinicaltrials |
| NCT05677958 | Protein Intake in Patients With Colorectal or Lung Cancer When Receiving a Nutritional Supplement(PROTEOS) | completed | N/A | 126 | Nutricia ResearchINDUSTRY | 7 | Jan 10, 2023 | clinicaltrials |
| NCT04442334 | The European NAFLD Registry | recruiting | — | 10,000 | Newcastle UniversityOTHER | 12 | Jan 6, 2023 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
| NCT05626764 | QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management | unknown | — | 3,000 | Hospices Civils de LyonOTHER | 4 | Nov 25, 2022 | clinicaltrials |
| NCT01597414 | Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 | completed | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Nov 17, 2022 | clinicaltrials |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients(BRAVO) | terminated | Phase 3 | 216 | Tesaro, Inc.INDUSTRY | 14 | Nov 15, 2022 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers SquibbINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT05070637 | Circulating Tumor Cell Reducing No-touch Nephrectomy(CITO-CERENE) | completed | N/A | 44 | Hospital de Santa Maria, PortugalOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | completed | Phase 3 | 1,718 | AmgenINDUSTRY | 29 | Nov 8, 2022 | clinicaltrials |
| NCT04460430 | Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer(NEREA) | terminated | Phase 2 | 12 | SOLTI Breast Cancer Research GroupOTHER | 2 | Oct 25, 2022 | clinicaltrials |
| NCT03816774 | Effect of Adding Simethicone to Split-dose Polyethylene Glycol for Bowel Preparation in a Screening Colonoscopy Setting | completed | N/A | 412 | Portuguese Oncology Institute, CoimbraOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04239365 | Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars | completed | N/A | 210 | Portuguese Oncology Institute, CoimbraOTHER | 1 | Oct 5, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials